The FDA recently approved Papzimeos (zopapogene imadenovec-drba), a new therapy from Precigen Inc., for the treatment of adults with recurrent respiratory papillomatosis (RRP). This marks
In the ever-evolving landscape of specialty pharmaceuticals, affordability and access remain front and center for patients, payers, and pharmacies alike. MedImpact Holdings Inc. is now
The FDA recently approved a new ORAL therapy, Brinsupri (brensocatib) from Insmed Inc., indicated for the treatment of non-cystic fibrosis bronchiectasis in adult and pediatric
We are all aware that orphan disease drugs are typically very expensive. Yet, health plans tend to avoid risk-sharing arrangements that could significantly mitigate those
The FDA recently approved a new ORAL therapy, Hernexeos (zongertinib tablets) from Boehringer Ingelheim, indicated for the treatment of adult patients with unresectable or metastatic
Navitus Health Solutions recently announced a significant development in its transparency-driven pharmacy benefit management model. Beginning January 1, 2026, its clients will gain access to
The FDA recently approved a new therapy, Zusduri (mitomycin) from UroGen Pharma. Zusduri, an alkylating drug, is indicated for the treatment of adult patients with
The FDA recently approved a new oral therapy, Zegfrovy (sunvozertinib) from Dizal (Jiangsu) Pharmaceutical Co., Ltd., for the treatment of adult patients with locally advanced
The 2025 JD Power US Pharmacy Study reveals significant shifts in pharmacy customer satisfaction and industry trends that pose major concerns for brick-and-mortar pharmacies. An
The FDA recently approved an ORAL therapy, Ekterly (sebetralstat) from KalVista Pharmaceuticals, indicated as an oral treatment for acute hereditary angioedema (HAE) attacks in patients
